Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.
Tuchman SA et al. J Geriatr Oncol. 2017 Feb 27. pii: S1879-4068(17)30030-9. doi: 10.1016/j.jgo.2017.02.004. [Epub ahead of print].

Carfilzomib containing combinations as frontline therapy for multiple myeloma: a meta analysis of 13 trials.
Sheng Z et al. Eur J Haematol. 2017 Mar 12. doi: 10.1111/ejh.12877. [Epub ahead of print].

Peripheral blood stem cell mobilization with a single dose of PEG-filgrastim in patients with multiple myeloma previously treated with radiotherapy.
Anguita-Compagnon AT et al. Leuk Lymphoma. 2017 Mar 16:1-4. doi: 10.1080/10428194.2017.1300895. [Epub ahead of print].

A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM et al. Biol Blood Marrow Transplant. 2017 Mar 8. pii: S1083-8791(17)30325-7. doi: 10.1016/j.bbmt.2017.03.007. [Epub ahead of print].

Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
Nair AP et al. Bone Marrow Transplant. 2017 Mar 20. doi: 10.1038/bmt.2017.37. [Epub ahead of print].

Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.
Einsele H et al. Leukemia. 2017 Mar 15. doi: 10.1038/leu.2017.83. [Epub ahead of print].

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
Ludwig H et al. Leuk Lymphoma. 2017 Mar 17:1-4. doi: 10.1080/10428194.2017.1298755. [Epub ahead of print].

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.
Suzuki K et al. Blood Cancer J. 2017 Mar 10;7(3):e540. doi: 10.1038/bcj.2017.18.

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed-Refractory to IMiDs and Proteasome Inhibitors.
Yalnız FF et al. Turk J Haematol. 2017 Mar 8. doi: 10.4274/tjh.2016.0397. [Epub ahead of print].

FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Gormley NJ et al. Clin Cancer Res. 2017 Mar 1. pii: clincanres.2870.2016. doi: 10.1158/1078-0432.CCR-16-2870. [Epub ahead of print].